Dabrafenib (CAS 1195765-45-7) BRAF Inhibitor Antitumor API

Dabrafenib (CAS 1195765-45-7) is a high-purity BRAF inhibitor antitumor API with a targeted mutation-selective mechanism. It selectively binds to and inhibits the activity of mutant BRAF kinases (V600E/K), blocking the downstream MAPK signaling pathway to suppress tumor cell proliferation and induce apoptosis, especially effective for BRAF-mutant melanoma and non-small cell lung cancer. Its refined crystalline form ensures consistent bioactivity and low impurity profiles, making it a reliable active ingredient for precision oncology pharmaceutical R&D.

Tailored for pharmaceutical manufacturers and precision oncology research institutions, this product adheres to strict international quality and regulatory standards. It addresses the core demand for BRAF-mutant targeted raw materials, supporting the development of formulations for melanoma, thyroid cancer and other BRAF-driven solid tumor research. Its stable chemical structure guarantees extended shelf life, facilitating flexible formulation design for oral preparations and clinical trial applications.